CHMP Issues Positive Opinion For Tablet Formulation Of Merck & Co., Inc. (MRK)’s NOXAFIL® (posaconazole)
2/28/2014 8:50:13 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational tablet formulation of NOXAFIL® (posaconazole).
Help employers find you! Check out all the jobs and post your resume.
comments powered by